MGMT promoter methylation in malignant gliomas: ready for personalized medicine? (Q37649471)

21 August 2017

1 reference

title

MGMT promoter methylation in malignant gliomas: ready for personalized medicine? (English)

1 reference

21 August 2017

main subject

personalized medicine

1 reference

1

Michael Weller

1 reference

21 August 2017

6

Wolfgang Wick

1 reference

21 August 2017

3

Guido Reifenberger

1 reference

21 August 2017

4

Alba A Brandes

1 reference

21 August 2017

Martin J van den Bent

series ordinal

5

object named as

Martin J van den Bent

1 reference

21 August 2017

7

Monika E Hegi

1 reference

21 August 2017

2

Roger Stupp

1 reference

21 August 2017

language of work or name

English

0 references

publication date

8 December 2009

1 reference

21 August 2017

published in

Nature Reviews Neurology

1 reference

21 August 2017

volume

6

1 reference

21 August 2017

issue

1

1 reference

21 August 2017

page(s)

39-51

1 reference

MGMT: its role in cancer aetiology and cancer therapeutics

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2009.197

MGMT: key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2009.197

Mismatch repair-dependent G2 checkpoint induced by low doses of SN1 type methylating agents requires the ATR kinase

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2009.197

Silencing effect of CpG island hypermethylation and histone modifications on O6-methylguanine-DNA methyltransferase (MGMT) gene expression in human cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2009.197

Identification of regions correlating MGMT promoter methylation and gene expression in glioblastomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2009.197

Correlation of tumor O6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: a Southwest Oncology Group study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2009.197

DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2009.197

Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2009.197

Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2009.197

Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2009.197

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2009.197

MGMT gene silencing and benefit from temozolomide in glioblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2009.197

NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2009.197

MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2009.197

Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2009.197

Infrequent promoter methylation of the MGMT gene in liver metastases from uveal melanoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2009.197

MGMT in primary and recurrent human glioblastomas after radiation and chemotherapy and comparison with p53 status and clinical outcome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2009.197

Progressive low-grade oligodendrogliomas: response to temozolomide and correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2009.197

Intratumoral homogeneity of MGMT promoter hypermethylation as demonstrated in serial stereotactic specimens from anaplastic astrocytomas and glioblastomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2009.197

Longitudinal assessment of genetic and epigenetic markers in oligodendrogliomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2009.197

Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2009.197

Precision and performance characteristics of bisulfite conversion and real-time PCR (MethyLight) for quantitative DNA methylation analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2009.197

MethyLight: a high-throughput assay to measure DNA methylation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2009.197

Validation of real-time methylation-specific PCR to determine O6-methylguanine-DNA methyltransferase gene promoter methylation in glioma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2009.197

Optimization of quantitative MGMT promoter methylation analysis using pyrosequencing and combined bisulfite restriction analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2009.197

MS-MLPA: an attractive alternative laboratory assay for robust, reliable, and semiquantitative detection of MGMT promoter hypermethylation in gliomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2009.197

Methylation-sensitive high resolution melting (MS-HRM): a new approach for sensitive and high-throughput assessment of methylation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2009.197

A microarray-based DNA methylation study of glioblastoma multiforme

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2009.197

Genomic profiling of CpG methylation and allelic specificity using quantitative high-throughput mass spectrometry: critical evaluation and improvements

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2009.197

Methylation of the DPYD promoter: an alternative mechanism for dihydropyrimidine dehydrogenase deficiency in cancer patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2009.197

Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2009.197

Synergistic antiglioma activity of radiotherapy and enzastaurin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2009.197

Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2009.197

Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2009.197

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2009.197

Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2009.197

Long-term survival with glioblastoma multiforme

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2009.197

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2009.197

Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2009.197

Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2009.197

Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2009.197

MGMT promoter hypermethylation correlates with a survival benefit from temozolomide in patients with recurrent anaplastic astrocytoma but not glioblastoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2009.197

Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2009.197

Mismatch repair deficiency does not mediate clinical resistance to temozolomide in malignant glioma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2009.197

MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2009.197

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2009.197

Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule: the "rescue" approach

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2009.197

Rechallenge with temozolomide in patients with recurrent gliomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2009.197

Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2009.197

Survival following adjuvant PCV or temozolomide for anaplastic astrocytoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2009.197

Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2009.197

Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment [...]

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2009.197

Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2009.197

Phase II study of protracted daily temozolomide for low-grade gliomas in adults

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2009.197

MGMT methylation: a marker of response to temozolomide in low-grade gliomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2009.197

MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2009.197

A novel tool to analyze MRI recurrence patterns in glioblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2009.197

Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: correlation With MGMT promoter methylation status

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2009.197

O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2009.197

Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2009.197

A simplified laboratory validated assay for MGMT promoter hypermethylation analysis of glioma specimens from formalin-fixed paraffin-embedded tissue

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2009.197

O6-benzylguanine suppression of O6-alkylguanine-DNA alkyltransferase in anaplastic gliomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2009.197

Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2009.197

Local intracerebral administration of O(6)-benzylguanine combined with systemic chemotherapy with temozolomide of a patient suffering from a recurrent glioblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2009.197

Long-term survival of patients with glioblastoma treated with radiotherapy and lomustine plus temozolomide

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2009.197

Chemoradiotherapy of newly diagnosed glioblastoma with intensified temozolomide

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2009.197

Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2009.197

MGMT prognostic impact on glioblastoma is dependent on therapeutic modalities

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2009.197

Promoter methylation and polymorphisms of the MGMT gene in glioblastomas: a population-based study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2009.197

Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2009.197

Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2009.197

Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2009.197

Methylation profiles of thirty four promoter-CpG islands and concordant methylation behaviours of sixteen genes that may contribute to carcinogenesis of astrocytoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2009.197

Hypermethylation of the DNA repair gene MGMT: association with TP53 G:C to A:T transitions in a series of 469 nervous system tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2009.197

Promoter methylation of the DNA repair gene MGMT in astrocytomas is frequently associated with G:C --> A:T mutations of the TP53 tumor suppressor gene

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2009.197

Phenotype versus genotype correlation in oligodendrogliomas and low-grade diffuse astrocytomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2009.197

Prognostic significance of O6-methylguanine-DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression in anaplastic gliomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2009.197

Correlation between promoter hypermethylation of the O6-methylguanine-deoxyribonucleic acid methyltransferase gene and prognosis in patients with high-grade astrocytic tumors treated with surgery, radiotherapy, and 1-(4-amino-2-methyl-5-pyrimidinyl)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2009.197

Concurrent hypermethylation of multiple genes is associated with grade of oligodendroglial tumors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2009.197

Correlation of clinical features and methylation status of MGMT gene promoter in glioblastomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2009.197

O6-methylguanine-DNA methyltransferase methylation and TP53 mutation in malignant astrocytomas and their relationships with clinical course

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2009.197

O6-methyl-guanine-DNA methyltransferase methylation in serum and tumor DNA predicts response to 1,3-bis(2-chloroethyl)-1-nitrosourea but not to temozolamide plus cisplatin in glioblastoma multiforme

31 March 2020

1 reference

12 December 2020

Apoptosis induced by DNA damage O6-methylguanine is Bcl-2 and caspase-9/3 regulated and Fas/caspase-8 independent

1 reference

12 December 2020

Repair of O(6)-alkylguanine by alkyltransferases

1 reference

12 December 2020

Retrospective study of the correlation between the DNA repair protein alkyltransferase and survival of brain tumor patients treated with carmustine

1 reference

12 December 2020

Anti-O6-methylguanine-methyltransferase (MGMT) immunohistochemistry in glioblastoma multiforme: observer variability and lack of association with patient survival impede its use as clinical biomarker

1 reference

12 December 2020

Promoter Hypermethylation of the DNA Repair Gene O6‐Methylguanine‐DNA Methyltransferase is an Independent Predictor of Shortened Progression Free Survival in Patients with Low‐grade Diffuse Astrocytomas

1 reference

12 December 2020

MGMT immunohistochemical expression and promoter methylation in human glioblastoma

1 reference

12 December 2020

In vivo selection of hematopoietic progenitor cells and temozolomide dose intensification in rhesus macaques through lentiviral transduction with a drug resistance gene

1 reference

12 December 2020

O(6)-methylguanine DNA-methyltransferase methylation status can change between first surgery for newly diagnosed glioblastoma and second surgery for recurrence: clinical implications

1 reference

12 December 2020

O6-methylguanine-DNA methyltransferase-deficient phenotype in human gliomas: frequency and time to tumor progression after alkylating agent-based chemotherapy

1 reference

12 December 2020

Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia

1 reference

12 December 2020

10.1038/NRNEUROL.2009.197

Identifiers

DOI

1 reference

21 August 2017

1 reference